Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
265.6 USD | +0.59% | -1.69% | -7.84% |
Apr. 17 | UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating | MT |
Apr. 16 | Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.84% | 142B | |
+28.76% | 676B | |
+24.28% | 554B | |
-7.47% | 349B | |
+14.55% | 318B | |
+7.73% | 291B | |
+3.15% | 210B | |
-0.31% | 204B | |
-10.02% | 194B | |
-11.83% | 144B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Barclays Adjusts Amgen's Price Target to $234 from $236, Maintains Equalweight Rating